BiotechTube

Moxifloxacin + Placebo + Lanifibranor + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Subjects

Conditions

Healthy Subjects

Trial Timeline

Jan 17, 2019 → Aug 27, 2019

NCT ID
NCT03866369

About Moxifloxacin + Placebo + Lanifibranor + Placebo

Moxifloxacin + Placebo + Lanifibranor + Placebo is a phase 1 stage product being developed by Inventiva for Healthy Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT03866369. Target conditions include Healthy Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03866369Phase 1Completed

Competing Products

20 competing products in Healthy Subjects

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Inventiva

IVA337 + PlaceboPhase 3
72
IVA337 + IVA337 + PlaceboPhase 2
47
IVA337 + PlaceboPhase 2
47
OdiparcilPhase 2
47
LanifibranorPhase 2
47